AG˹ٷ

STOCK TITAN

[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

RAPT Therapeutics, Inc. (RAPT) � Form 4 insider filing

On June 21 2025, director Ashley L. Dombkowski received a new equity award consisting of 25,000 non-qualified stock options with an exercise price of $7.43 per share. The options were reported under transaction code “A� (grant) and are held directly by the reporting person.

Vesting schedule: the grant vests in three equal annual installments over a three-year period starting from the grant date (i.e., approximately 8,333 options per year through June 21 2028). The options expire on June 21 2035.

Following this award, Dombkowski beneficially owns 25,000 derivative securities (stock options). No open-market purchases or sales of common stock were reported, and there were no changes in non-derivative share ownership.

The filing reflects routine director compensation and does not include any other material transactions or earnings information.

RAPT Therapeutics, Inc. (RAPT) � Comunicazione interna Modulo 4

Il 21 giugno 2025, la direttrice Ashley L. Dombkowski ha ricevuto un nuovo premio azionario consistente in 25.000 opzioni su azioni non qualificate con un prezzo di esercizio di $7,43 per azione. Le opzioni sono state segnalate con il codice transazione “A� (assegnazione) e sono detenute direttamente dalla persona che ha effettuato la segnalazione.

Piano di maturazione: il premio matura in tre rate annuali uguali nell’arco di tre anni a partire dalla data di assegnazione (ossia circa 8.333 opzioni all’anno fino al 21 giugno 2028). Le opzioni scadono il 21 giugno 2035.

Dopo questo premio, Dombkowski detiene beneficiariamente 25.000 strumenti derivati (opzioni su azioni). Non sono stati segnalati acquisti o vendite sul mercato aperto di azioni ordinarie, né variazioni nella proprietà di azioni non derivate.

La comunicazione riflette la normale remunerazione del direttore e non include altre transazioni rilevanti o informazioni sugli utili.

RAPT Therapeutics, Inc. (RAPT) � Presentación interna Formulario 4

El 21 de junio de 2025, la directora Ashley L. Dombkowski recibió un nuevo premio de acciones que consiste en 25,000 opciones sobre acciones no calificadas con un precio de ejercicio de $7.43 por acción. Las opciones fueron reportadas bajo el código de transacción “A� (adjudicación) y son mantenidas directamente por la persona que reporta.

Calendario de consolidación: el premio se consolida en tres cuotas anuales iguales durante un período de tres años a partir de la fecha de adjudicación (es decir, aproximadamente 8,333 opciones por año hasta el 21 de junio de 2028). Las opciones vencen el 21 de junio de 2035.

Tras este premio, Dombkowski posee beneficiariamente 25,000 valores derivados (opciones sobre acciones). No se reportaron compras ni ventas en el mercado abierto de acciones comunes, ni cambios en la propiedad de acciones no derivadas.

La presentación refleja la compensación rutinaria del director y no incluye ninguna otra transacción material ni información sobre ganancias.

RAPT Therapeutics, Inc. (RAPT) � 내부� 보고� Form 4

2025� 6� 21�, 이사 Ashley L. Dombkowski� 주당 $7.43� 행사 가격으� 구성� 25,000개의 비자� 주식 매수선택�� 포함하는 새로� 주식 보상� 받았습니�. � 옵션들은 거래 코드 “A� (부�)� 보고되었으며 보고자가 직Ϊ 보유하고 있습니다.

권리 확정 일정: � 보상은 부여일로부� 3년간 매년 동일� � 부분으� 나누� 확정되며(�, 2028� 6� 21일까지 연간 � 8,333 옵션), 옵션 만료일은 2035� 6� 21�입니�.

이번 보상 이후 Dombkowski� 25,000개의 파생증권(주식 매수선택�)� 실질적으� 보유하게 되었습니�. 보통주에 대� 공개 시장 매수 또는 매도� 보고되지 않았으며, 비파� 주식 소유� 변동도 없었습니�.

이번 보고� 일반적인 이사 보상� 관� 것으�, 다른 중요� 거래� 수익 정보� 포함하지 않습니다.

RAPT Therapeutics, Inc. (RAPT) � Déclaration d’initié Formulaire 4

Le 21 juin 2025, la directrice Ashley L. Dombkowski a reçu une nouvelle attribution d’actions comprenant 25 000 options d’achat d’actions non qualifiées avec un prix d’exercice de 7,43 $ par action. Les options ont été déclarées sous le code de transaction « A » (octroi) et sont détenues directement par la personne déclarante.

Calendrier d’acquisition : l’attribution se consolide en trois versements annuels égaux sur une période de trois ans à partir de la date d’octroi (soit environ 8 333 options par an jusqu’au 21 juin 2028). Les options expirent le 21 juin 2035.

Suite à cette attribution, Dombkowski détient de manière bénéficiaire 25 000 titres dérivés (options d’achat d’actions). Aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a été signalé, et il n’y a eu aucun changement dans la détention d’actions non dérivées.

La déclaration reflète la rémunération habituelle du directeur et n’inclut aucune autre transaction importante ni information sur les gains.

RAPT Therapeutics, Inc. (RAPT) � Insider-Meldung Formular 4

Am 21. Juni 2025 erhielt die Direktorin Ashley L. Dombkowski eine neue Aktienzuteilung bestehend aus 25.000 nicht qualifizierten Aktienoptionen mit einem Ausübungspreis von 7,43 $ pro Aktie. Die Optionen wurden unter dem Transaktionscode „A� (Gewährung) gemeldet und werden direkt von der meldenden Person gehalten.

Vesting-Plan: Die Zuteilung wird in drei gleichen jährlichen Raten über einen Zeitraum von drei Jahren ab dem Zuteilungsdatum fällig (d.h. ca. 8.333 Optionen pro Jahr bis zum 21. Juni 2028). Die Optionen verfallen am 21. Juni 2035.

Nach dieser Zuteilung besitzt Dombkowski wirtschaftlich 25.000 derivative Wertpapiere (Aktienoptionen). Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt gemeldet, und es gab keine Änderungen im Besitz von nicht-derivativen Aktien.

Die Meldung spiegelt die routinemäßige Vergütung des Direktors wider und enthält keine weiteren wesentlichen Transaktionen oder Gewinninformationen.

Positive
  • Aligns director incentives with long-term shareholder value via a 10-year option grant.
  • Three-year vesting encourages continued board service and strategic continuity.
Negative
  • No open-market share purchase; the filing does not indicate additional insider cash investment.
  • Potential albeit minimal dilution if options are exercised in the future.

Insights

TL;DR: Director granted 25k options at $7.43; routine, modest alignment, neutral market impact.

This Form 4 records a single, standard director stock-option grant. At-the-money awards with decade-long terms and three-year vesting are typical for biotech boards. While the grant aligns the director’s incentives with shareholders, it does not involve cash outlay or immediate share accumulation, so signaling value is limited. With only 25,000 options, dilution is immaterial relative to RAPT’s 33 million share base. Overall impact on valuation or float is negligible.

RAPT Therapeutics, Inc. (RAPT) � Comunicazione interna Modulo 4

Il 21 giugno 2025, la direttrice Ashley L. Dombkowski ha ricevuto un nuovo premio azionario consistente in 25.000 opzioni su azioni non qualificate con un prezzo di esercizio di $7,43 per azione. Le opzioni sono state segnalate con il codice transazione “A� (assegnazione) e sono detenute direttamente dalla persona che ha effettuato la segnalazione.

Piano di maturazione: il premio matura in tre rate annuali uguali nell’arco di tre anni a partire dalla data di assegnazione (ossia circa 8.333 opzioni all’anno fino al 21 giugno 2028). Le opzioni scadono il 21 giugno 2035.

Dopo questo premio, Dombkowski detiene beneficiariamente 25.000 strumenti derivati (opzioni su azioni). Non sono stati segnalati acquisti o vendite sul mercato aperto di azioni ordinarie, né variazioni nella proprietà di azioni non derivate.

La comunicazione riflette la normale remunerazione del direttore e non include altre transazioni rilevanti o informazioni sugli utili.

RAPT Therapeutics, Inc. (RAPT) � Presentación interna Formulario 4

El 21 de junio de 2025, la directora Ashley L. Dombkowski recibió un nuevo premio de acciones que consiste en 25,000 opciones sobre acciones no calificadas con un precio de ejercicio de $7.43 por acción. Las opciones fueron reportadas bajo el código de transacción “A� (adjudicación) y son mantenidas directamente por la persona que reporta.

Calendario de consolidación: el premio se consolida en tres cuotas anuales iguales durante un período de tres años a partir de la fecha de adjudicación (es decir, aproximadamente 8,333 opciones por año hasta el 21 de junio de 2028). Las opciones vencen el 21 de junio de 2035.

Tras este premio, Dombkowski posee beneficiariamente 25,000 valores derivados (opciones sobre acciones). No se reportaron compras ni ventas en el mercado abierto de acciones comunes, ni cambios en la propiedad de acciones no derivadas.

La presentación refleja la compensación rutinaria del director y no incluye ninguna otra transacción material ni información sobre ganancias.

RAPT Therapeutics, Inc. (RAPT) � 내부� 보고� Form 4

2025� 6� 21�, 이사 Ashley L. Dombkowski� 주당 $7.43� 행사 가격으� 구성� 25,000개의 비자� 주식 매수선택�� 포함하는 새로� 주식 보상� 받았습니�. � 옵션들은 거래 코드 “A� (부�)� 보고되었으며 보고자가 직Ϊ 보유하고 있습니다.

권리 확정 일정: � 보상은 부여일로부� 3년간 매년 동일� � 부분으� 나누� 확정되며(�, 2028� 6� 21일까지 연간 � 8,333 옵션), 옵션 만료일은 2035� 6� 21�입니�.

이번 보상 이후 Dombkowski� 25,000개의 파생증권(주식 매수선택�)� 실질적으� 보유하게 되었습니�. 보통주에 대� 공개 시장 매수 또는 매도� 보고되지 않았으며, 비파� 주식 소유� 변동도 없었습니�.

이번 보고� 일반적인 이사 보상� 관� 것으�, 다른 중요� 거래� 수익 정보� 포함하지 않습니다.

RAPT Therapeutics, Inc. (RAPT) � Déclaration d’initié Formulaire 4

Le 21 juin 2025, la directrice Ashley L. Dombkowski a reçu une nouvelle attribution d’actions comprenant 25 000 options d’achat d’actions non qualifiées avec un prix d’exercice de 7,43 $ par action. Les options ont été déclarées sous le code de transaction « A » (octroi) et sont détenues directement par la personne déclarante.

Calendrier d’acquisition : l’attribution se consolide en trois versements annuels égaux sur une période de trois ans à partir de la date d’octroi (soit environ 8 333 options par an jusqu’au 21 juin 2028). Les options expirent le 21 juin 2035.

Suite à cette attribution, Dombkowski détient de manière bénéficiaire 25 000 titres dérivés (options d’achat d’actions). Aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a été signalé, et il n’y a eu aucun changement dans la détention d’actions non dérivées.

La déclaration reflète la rémunération habituelle du directeur et n’inclut aucune autre transaction importante ni information sur les gains.

RAPT Therapeutics, Inc. (RAPT) � Insider-Meldung Formular 4

Am 21. Juni 2025 erhielt die Direktorin Ashley L. Dombkowski eine neue Aktienzuteilung bestehend aus 25.000 nicht qualifizierten Aktienoptionen mit einem Ausübungspreis von 7,43 $ pro Aktie. Die Optionen wurden unter dem Transaktionscode „A� (Gewährung) gemeldet und werden direkt von der meldenden Person gehalten.

Vesting-Plan: Die Zuteilung wird in drei gleichen jährlichen Raten über einen Zeitraum von drei Jahren ab dem Zuteilungsdatum fällig (d.h. ca. 8.333 Optionen pro Jahr bis zum 21. Juni 2028). Die Optionen verfallen am 21. Juni 2035.

Nach dieser Zuteilung besitzt Dombkowski wirtschaftlich 25.000 derivative Wertpapiere (Aktienoptionen). Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt gemeldet, und es gab keine Änderungen im Besitz von nicht-derivativen Aktien.

Die Meldung spiegelt die routinemäßige Vergütung des Direktors wider und enthält keine weiteren wesentlichen Transaktionen oder Gewinninformationen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dombkowski Ashley L.

(Last) (First) (Middle)
C/O RAPT THERAPEUTICS, INC.
561 ECCLES AVENUE

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Option (right to buy) $7.43 06/21/2025 A 25,000 (1) 06/21/2035 Common Stock 25,000 $0 25,000 D
Explanation of Responses:
1. The shares subject to the option shall vest in three successive equal annual installments over the three-year period measured from the date of grant of June 21, 2025.
/s/ Rodney Young, Attorney-in-Fact, Attorney-in-Fact 06/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did RAPT director Ashley Dombkowski report on the latest Form 4?

She received 25,000 stock options at an exercise price of $7.43 on June 21 2025.

When do the newly granted RAPT options vest?

They vest in three equal annual installments over the three-year period beginning June 21 2025.

What is the expiration date of the RAPT stock-option grant?

The options expire on June 21 2035.

Did the director buy or sell RAPT common shares in this filing?

No. The Form 4 shows only an option grant; there were no purchases or sales of common stock.

How many derivative securities does the director own after the transaction?

Ashley Dombkowski now holds 25,000 derivative securities (stock options) directly.
Rapt Therapeutics, Inc.

NASDAQ:RAPT

RAPT Rankings

RAPT Latest News

RAPT Latest SEC Filings

RAPT Stock Data

123.03M
12.71M
0.49%
96.43%
1.99%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO